ETH spin-out Covagen raises further funding

Funding

Covagen, an ETH Zurich spin-out company pioneering the development of a novel class of protein therapeutics called fynomers, has announced the closing of a financing round with its existing shareholder Ventech and a new investor Edmond de Rothschild Investment Partners (EdRIP). The amount was not disclosed. Gilles Nobécourt will join Covagen’s Board of Directors as representative of EdRIP.

“We are very pleased that we could attract additional funding and add EdRIP to Covagen’s investor syndicate. The additional investment provided by Ventech and EdRIP validates the interest in our technology and therapeutic programs”, said Julian Bertschinger, Chief Executive Officer of Covagen.